Berg AR, et al. - Authors evaluated retrospectively, the charts of 1580 cases who underwent total joint arthroplasty (TJA) between 2014 and 2017 to delineate the impact of transdermal scopolamine on the rates of postoperative nausea and vomiting (PONV) and functional outcomes following TJA. Significantly lower incidence of PONV was reported in the study group vs control group (14.4% vs 29.3%). They found lower Visual Analog Scale pain scores on postoperative days (POD) 0 through 2 among subjects who were given scopolamine. They were able to walk further distances on POD 0 through 3 and received fewer morphine equivalents on POD 1 and 2. On POD 0, the study group received greater morphine equivalents.